<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40968755</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-5548</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Diabetes care</Title><ISOAbbreviation>Diabetes Care</ISOAbbreviation></Journal><ArticleTitle>Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dc251673</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2337/dc25-1673</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The CONFIDENCE trial demonstrated additive benefits of simultaneous initiation of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter 2 (SGLT2) inhibitor compared with monotherapy in reducing the urinary albumin-to-creatinine ratio (UACR). This prespecified analysis evaluated whether safety and efficacy of combination therapy varies by baseline glucagon-like peptide 1 receptor agonist (GLP-1 RA) use.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">Adults with chronic kidney disease (UACR &#x2265;100 to &lt;5,000 mg/g; estimated glomerular filtration rate [eGFR] 30-90 mL/min/1.73 m2) and type 2 diabetes (glycated hemoglobin &lt;11% [97 mmol/mol]) were randomized (1:1:1) to once-daily finerenone, empagliflozin, or finerenone plus empagliflozin.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 800 participants, 182 (23%) used a GLP-1 RA at baseline. At day 180, UACR change from baseline in participants using a GLP-1 RA was -51% (95% CI -59 to -40%) with combination therapy, -34% (-48 to -18%) with finerenone, and -36% (-48 to -21%) with empagliflozin. Corresponding results in those not using a GLP-1 RA at baseline were -56% (-62 to -50%), -37% (-45 to -28%), and -33% (-41 to -23%), respectively. Hyperkalemia incidence rates with combination therapy were 9.0% and 9.5% among individuals with and without baseline GLP-1 RA use. eGFR changes were consistent among individuals with and without baseline GLP-1 RA use. Acute kidney injury was uncommon. Decreases in systolic blood pressure were observed and were more pronounced with combination therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In CONFIDENCE, simultaneous initiation with finerenone and an SGLT2 inhibitor was effective and well tolerated compared with monotherapy, irrespective of background use of a GLP-1 RA.</AbstractText><CopyrightInformation>&#xa9; 2025 by the American Diabetes Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8355-7100</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Jennifer B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-9967-5352</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heerspink</LastName><ForeName>Hiddo J L</ForeName><Initials>HJL</Initials><Identifier Source="ORCID">0000-0002-3126-3730</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Johannes F E</ForeName><Initials>JFE</Initials><AffiliationInfo><Affiliation>KfH Kidney Centre, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, Friedrich Alexander University, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGill</LastName><ForeName>Janet B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis School of Medicine, St. Louis, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mottl</LastName><ForeName>Amy K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-4258-1726</Identifier><AffiliationInfo><Affiliation>University of North Carolina Kidney Center, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nangaku</LastName><ForeName>Masaomi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenstock</LastName><ForeName>Julio</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8324-3275</Identifier><AffiliationInfo><Affiliation>Velocity Clinical Research at Medical City, Dallas, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaduganathan</LastName><ForeName>Muthiah</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0885-1953</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinker</LastName><ForeName>Meike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Charlie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Statistics and Analytics, Bayer US LLC, Whippany, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Bayer AG, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bayer Healthcare, Chaoyang District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohwedder</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Bayer AG, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossing</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1531-4294</Identifier><AffiliationInfo><Affiliation>Steno Diabetes Center Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Pharmaceuticals Bayer</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Care</MedlineTA><NlmUniqueID>7805975</NlmUniqueID><ISSNLinking>0149-5992</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40968755</ArticleId><ArticleId IdType="doi">10.2337/dc25-1673</ArticleId><ArticleId IdType="pii">163403</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>